Psilocybin for the Treatment of Migraine Headache

Randomised, double-blind, crossover design in adults with migraine: each subject receives placebo and a psilocybin dose approximately 14 days apart with randomised order and assignment to low or high dose.

Participants maintain headache diaries to record frequency, intensity and associated symptoms; this preliminary study will inform design of larger trials.